Dextenza is an intracanalicular insert that delivers a 0.4mg dose of dexamethasone, a corticosteroid, for up to 30 days following insertion.

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

The FDA has expanded the approval of Dextenza (dexamethasone ophthalmic insert) to include pediatric treatment.

Oculis Holding has concluded subject enrolment for the Phase III DIAMOND-1 and DIAMOND-2 clinical trials of OCS-01 eye drops ...

The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...